Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2C | Q14957 | 8/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416858 | 0.90 | GRIN2C (0.56) | GRIN2CCA12CA1CA2CA7 | |
| SCHEMBL4414956 | 0.89 | GRIN2C (0.54) | GRIN2CCA12CA1CA2CA7 | |
| SCHEMBL4416759 | 0.86 | GRIN2C (0.53) | GRIN2CCA12CA1CA2CA7 | |
| SCHEMBL4411732 | 0.85 | GRIN2C (0.56) | GRIN2CCA12CA1CA2CA7 | |
| SCHEMBL4422268 | 0.85 | GRIN2C (0.55) | GRIN2CCA12CA1CA2CA7 | |
| SCHEMBL4418463 | 0.84 | GRIN2C (0.53) | GRIN2CTAS1R3TAS1R1TAS1R2MEN1 | |
| SCHEMBL4411776 | 0.82 | NPC1 (0.53) | GRIN2CCA12CA1CA2CA7 | |
| SCHEMBL6509279 | 0.82 | GRIN2C (0.52) | GRIN2CCA12CA1CA2CA7 | |
| SCHEMBL13972637 | 0.81 | GRIN2C (0.47) | GRIN2CCA12CA1CA2CA7 | |
| SCHEMBL4422046 | 0.81 | GRIN2C (0.51) | GRIN2CCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | GRIN2C 567/4885TAS1R3 669/4885TAS1R1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.